YS Biopharma Changes Name to LakeShore Biopharma
Ticker: LSBWF · Form: 6-K · Filed: May 24, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: name-change, rebranding
TL;DR
YS Biopharma is now LakeShore Biopharma, effective 9/12/22. Rebranding alert!
AI Summary
YS Biopharma Co., Ltd. announced a name change to LakeShore Biopharma, effective September 12, 2022. The company, previously known as YishengBio Co., Ltd., is a pharmaceutical preparations company based in Beijing, PRC.
Why It Matters
A company name change can signal a strategic shift or rebranding effort, potentially impacting investor perception and market positioning.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a name change and does not involve financial transactions or operational changes that would inherently increase risk.
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Registrant
- LakeShore Biopharma (company) — New Company Name
- YishengBio Co., Ltd. (company) — Former Company Name
- September 12, 2022 (date) — Date of Name Change
FAQ
What is the new name of YS Biopharma Co., Ltd.?
The new name of YS Biopharma Co., Ltd. is LakeShore Biopharma.
When did the name change become effective?
The name change became effective on September 12, 2022.
What was the former name of the company?
The former name of the company was YishengBio Co., Ltd.
What is the primary business of YS Biopharma?
YS Biopharma is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is YS Biopharma's principal executive office located?
YS Biopharma's principal executive office is located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Filing Stats: 171 words · 1 min read · ~1 pages · Grade level 9.4 · Accepted 2024-05-24 07:45:05
Filing Documents
- ea0206847-6k_ysbio.htm (6-K) — 11KB
- ea020684701ex99-1_ysbio.htm (EX-99.1) — 5KB
- 0001213900-24-046403.txt ( ) — 17KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-41598 YS BIOPHARMA CO., LTD. (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release – YS Biopharma Announces Name Change to LakeShore Biopharma 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. By: /s/ Hui Shao Name: Hui Shao Title: Director and Co-Chief Executive Officer Date: May 24, 2024 2